ALAYNA MIHILL: Open Payments
NPI 1194596411 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$828 in 46 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $469 · 2025 $828
Food & beverage: $828
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $159 |
| Ipsen Biopharmaceuticals, Inc | 5 | $127 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $81 |
| Ardelyx, Inc. | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| GENZYME CORPORATION | 3 | $65 |
| ABBVIE INC. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Janssen Biotech, Inc. | 1 | $26 |
| Gilead Sciences, Inc. | 1 | $23 |
Products named: ENTYVIO, DUPIXENT, IQIRVO, IBSRELA, XIFAXAN, VOQUEZNA, RINVOQ, TREMFYA.
Industry payments across VA — which companies pay providers there.
